This golden autumn, SINOPEG ventured to Europe with its innovative products and solutions, making consecutive appearances at two premier international industry exhibitions within two months, engaging in deep exchanges with global pharmaceutical elites. CPHI Frankfurt 2025 (Frankfurt, Germany, Oct 28-30) As the world's largest and most influential professional event for the pharmaceutical industry, CPHI Frankfurt brought together industry elites from across the globe. In this grand gathering, SINOPEG attracted numerous visitors with its professional technical sharing. During the exhibition, we prominently showcased our latest achievements in areas such as in vivo CAR-T delivery, Antibody-Drug Conjugate (ADC) linkers, and block copolymers. We held in-depth discussions with multiple potential clients and partners from Europe, North America, and Asia! Many international clients praised our continuously improving R&D capabilities and product quality control system. TIDES Europe 2025 (Basel, Switzerland, Nov 11-13) Following closely, we moved to Switzerland to participate in TIDES Europe, an exhibition focused on oligonucleotides, peptides, mRNA therapies, and related fields. As one of the fastest-growing segments in biopharmaceuticals, TIDES provided us with a valuable platform for direct dialogue with global top experts. Here, we shared SINOPEG's technical expertise and project experience in fatty acid-modified side chains, LNP delivery material production, and related CMC services, attracting numerous biotechnology companies seeking reliable CDMO partners in this field. Through exchanges with industry benchmark companies, we further clarified our future technological development direction and innovation priorities. The successful participation in these two consecutive exhibitions allowed us to clearly grasp the development pulse of the global pharmaceutical industry chain. We deeply felt that CDMO enterprises from China are increasingly winning the trust of the global market, thanks to their continuously enhancing technical capabilities, flexible service models, and reliable quality systems. Two expeditions, two stages of growth. We brought back customer recognition, partner trust, and market insights – all of which will be invaluable assets for SINOPEG's future development! SINOPEG's journey on the international stage has just begun. We will continue to deepen our core technologies and expand our global footprint. Next year, we will appear on broader international stages, bringing more innovative solutions 'Made in China' to the global pharmaceutical industry. Stay tuned!

Product Name: XcellFect RNA Transfection Reagent Catalog No.: D7010101 Storage: Sealed at 4°C. Avoid repeated freeze-thaw cycles. Why Choose XcellFect? High Efficiency, Low Toxicity: Powered by our patented lipid-based formulation, XcellFect overcomes traditional delivery bottlenecks to deliver ultra-high transfection efficiency while maintaining minimal cytotoxicity. Say goodbye to compromised cell viability! Broad Spectrum Compatibility: Designed for versatility, XcellFect works seamlessly across common cell lines and is specially optimized for hard-to-transfect cells. No more struggling with inconsistent results! Multi-RNA Flexibility: Whether you’re working with siRNA, mRNA, miRNA, or other RNA types, XcellFect ensures robust delivery for diverse applications—from gene silencing to therapeutic development. Streamlined Workflow: Just mix Reagent A and B, combine with RNA, and add to cells—no media replacement needed! Compatible with complete culture media, saving you time and simplifying protocols. Ideal For: Gene function studies Therapeutic RNA delivery CRISPR-Cas9 workflows High-throughput screening ransform Your Research Today! contact our team at polydarwin@sinopeg.com to learn more or request a sample. Let XcellFect accelerate your breakthroughs in RNA-based science!

Review Mol Ther. 2017 Jul 5;25(7):1467-1475.  doi: 10.1016/j.ymthe.2017.03.013.  Epub 2017 Apr 13. Lipid Nanoparticle Systems for Enabling Gene Therapies Abstract Genetic drugs such as small interfering RNA (siRNA), mRNA, or plasmid DNA provide potential gene therapies to treat most diseases by silencing pathological genes, expressing therapeutic proteins, or through gene-editing applications.  In order for genetic drugs to be used clinically, however, sophisticated delivery systems are required.  Lipid nanoparticle (LNP) systems are currently the lead non-viral delivery systems for enabling the clinical potential of genetic drugs.  Application will be made to the Food and Drug Administration (FDA) in 2017 for approval of an LNP siRNA drug to treat transthyretin-induced amyloidosis, presently an untreatable disease.  Here, we first review research leading to the development of LNP siRNA systems capable of silencing target genes in hepatocytes following systemic administration.  Subsequently, progress made to extend LNP technology to mRNA and plasmids for protein replacement, vaccine, and gene-editing applications is summarized.  Finally, we address current limitations of LNP technology as applied to genetic drugs and ways in which such limitations may be overcome.  It is concluded that LNP technology, by virtue of robust and efficient formulation processes, as well as advantages in potency, payload, and design flexibility, will be a dominant non-viral technology to enable the enormous potential of gene therapy. Keywords: gene editing;  gene therapy;  genetic drugs;  lipid nanoparticles;  mRNA;  siRNA. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com